Biodesix Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $102.9M+44.3% YoYTTM through 30 Jun 2026
Net Income -$27.8MTTM through 30 Jun 2026
Free Cash Flow -$20.2MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 84.0% |
| EBITDA Margin | -14.6% |
| Operating Margin | -24.3% |
| Net Margin | -27.0% |
Returns
-350.0%ROE
-33.8%ROA
Balance Sheet Health
Debt / Equity5.48x
Current Ratio1.86x
Net Debt$24.4M
Cash & Equivalents$30M
Quality Metrics
Altman Z-Score-4.74
Piotroski F-Score5 / 9
FCF Margin-19.7%
Rule of 40-11.8
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2025: $88.5M
Diluted EPS-$3.10TTMFY2025: $-4.67
Dividend
No dividend
Capital Allocation
R&D Spend$12.3M
Capex Intensity0.4%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Diagnostic Tests | $22.3M | +36.6% | View detailsDriven by increasing sales productivity and expanded clinical evidence supporting the Nodify Lung tests. |
| Development Services | $32.6M | +98.8% | View detailsGrowth supported by continued execution on existing contracts and the addition of new Development Services agreements. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.